Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tony Reid

Showing results (41-50 of 125) with videos related to

Pageof 13
Sort By:
Tropical Medicine & International Health : TM & IH|July 11, 2013
'I cry every day': experiences of patients co-infected with HIV and multidrug-resistant tuberculosisPetros Isaakidis, Sheela Rangan, Anagha Pradhan, et al.
Frontiers in Oncology|June 21, 2023
A multicenter, phase 1, dose escalation clinical trial (G-FORCE-1) of XRT, RRx-001 and temozolomide followed by temozolomide +/- RRx-001 in newly diagnosed glioblastomaHoward Fine, Tony Reid, Scott Caroen, et al.
Plos One|December 30, 2015
Direct Observation (DO) for Drug-Resistant Tuberculosis: Do We Really DO?Stella Benbaba, Petros Isaakidis, Mrinalini Das, et al.
Expert Opinion on Drug Delivery|April 26, 2020
Rationale and necessity for delivery of RRx-001, a Myc and CD47 antagonist, by intravenous blood mixScott Caroen, Bryan Oronsky, Corey Carter, et al.
Recent Patents on Biotechnology|January 13, 2023
Patent and Marketing Exclusivities 101 for Drug DevelopersBryan Oronsky, Scott Caroen, Franck Brinkhaus, et al.
Transactions of the Royal Society of Tropical Medicine and Hygiene|October 7, 2008
Weight evolution in HIV-1 infected women in Rwanda after stavudine substitution due to lipoatrophy: comparison of zidovudine with tenofovir/abacavirJohan van Griensven, Rony Zachariah, Freya Rasschaert, et al.
Frontiers in Oncology|June 14, 2023
RRx-001: a chimeric triple action NLRP3 inhibitor, Nrf2 inducer, and nitric oxide superagonistBryan Oronsky, Lori Takahashi, Richard Gordon, et al.
Cytokine & Growth Factor Reviews|May 18, 2010
Navigating the clinical development landscape for oncolytic viruses and other cancer therapeutics: no shortcuts on the road to approvalCaroline J Breitbach, Tony Reid, James Burke, et al.
Theranostics|June 20, 2013
Real time dynamic imaging and current targeted therapies in the war on cancer: a new paradigmRamasamy Paulmurugan, Bryan Oronsky, Chad F Brouse, et al.
Cancers|October 14, 2022
Oncolytic Adenoviruses: The Cold War against Cancer Finally Turns HotBryan Oronsky, Brian Gastman, Anthony P Conley, et al.
Pageof 13

Showing results (41-50 of 125) with videos related to

Sort By:
Pageof 13
Tropical Medicine & International Health : TM & IH|July 11, 2013
'I cry every day': experiences of patients co-infected with HIV and multidrug-resistant tuberculosisPetros Isaakidis, Sheela Rangan, Anagha Pradhan, et al.
Frontiers in Oncology|June 21, 2023
A multicenter, phase 1, dose escalation clinical trial (G-FORCE-1) of XRT, RRx-001 and temozolomide followed by temozolomide +/- RRx-001 in newly diagnosed glioblastomaHoward Fine, Tony Reid, Scott Caroen, et al.
Plos One|December 30, 2015
Direct Observation (DO) for Drug-Resistant Tuberculosis: Do We Really DO?Stella Benbaba, Petros Isaakidis, Mrinalini Das, et al.
Expert Opinion on Drug Delivery|April 26, 2020
Rationale and necessity for delivery of RRx-001, a Myc and CD47 antagonist, by intravenous blood mixScott Caroen, Bryan Oronsky, Corey Carter, et al.
Recent Patents on Biotechnology|January 13, 2023
Patent and Marketing Exclusivities 101 for Drug DevelopersBryan Oronsky, Scott Caroen, Franck Brinkhaus, et al.
Transactions of the Royal Society of Tropical Medicine and Hygiene|October 7, 2008
Weight evolution in HIV-1 infected women in Rwanda after stavudine substitution due to lipoatrophy: comparison of zidovudine with tenofovir/abacavirJohan van Griensven, Rony Zachariah, Freya Rasschaert, et al.
Frontiers in Oncology|June 14, 2023
RRx-001: a chimeric triple action NLRP3 inhibitor, Nrf2 inducer, and nitric oxide superagonistBryan Oronsky, Lori Takahashi, Richard Gordon, et al.
Cytokine & Growth Factor Reviews|May 18, 2010
Navigating the clinical development landscape for oncolytic viruses and other cancer therapeutics: no shortcuts on the road to approvalCaroline J Breitbach, Tony Reid, James Burke, et al.
Theranostics|June 20, 2013
Real time dynamic imaging and current targeted therapies in the war on cancer: a new paradigmRamasamy Paulmurugan, Bryan Oronsky, Chad F Brouse, et al.
Cancers|October 14, 2022
Oncolytic Adenoviruses: The Cold War against Cancer Finally Turns HotBryan Oronsky, Brian Gastman, Anthony P Conley, et al.
Pageof 13